HUTCHMED (China) Limited (HCM) RNS Announcements

Add to Alert list
Date Time Source Announcement
07 Mar 2016 07:59 AM
RNS
Fifth Filing of Form F-1 Registration Statement
04 Mar 2016 06:12 PM
RNS
Launch of Potential U.S. Public Offering of ADSs
04 Mar 2016 05:54 PM
RNS
Fifth Filing of Form F-1 Registration Statement
02 Mar 2016 07:00 AM
RNS
Sulfatinib Phase II initation in thyroid cancer
01 Mar 2016 07:00 AM
RNS
Final Results
11 Feb 2016 05:39 PM
RNS
Public Filing of Form F-1 Registration Statement
29 Jan 2016 08:03 AM
RNS
Notice of Results
15 Jan 2016 07:02 AM
RNS
Chi-Med initiates HMPL-523 Phase I clinical trial
29 Dec 2015 07:43 AM
RNS
Blocklisting Six Monthly Return
18 Dec 2015 07:00 AM
RNS
Initiation sulfatinib Phase III registration study
09 Dec 2015 07:00 AM
RNS
US$105 m Shanghai land compensation agreement
08 Dec 2015 07:00 AM
RNS
Initiation of fruquintinib Phase 3 trial in NSCLC
13 Nov 2015 02:50 PM
RNS
Second Public Filing of Registration Statement
10 Nov 2015 01:13 PM
RNS
Results of Extraordinary General Meeting
09 Nov 2015 07:59 AM
RNS
Director/PDMR Shareholding
06 Nov 2015 07:00 AM
RNS
Chi-Med initiates sulfatinib U.S. clinical trials
30 Oct 2015 07:00 AM
RNS
Clinical results presented
30 Oct 2015 07:00 AM
RNS
Total Voting Rights
30 Oct 2015 07:00 AM
RNS
Completion of Phase I clinical trial of HMPL 523
23 Oct 2015 07:00 AM
RNS
Milestone Payment from Lilly Triggered
20 Oct 2015 02:40 PM
RNS
Director's Share Dealing
19 Oct 2015 07:00 AM
RNS
Awards under Long Term Incentive Plan
16 Oct 2015 12:17 PM
RNS
Shareholders' Circular and Notice of EGM
16 Oct 2015 12:15 PM
RNS
Filing of Registration Statement on Form F1
16 Oct 2015 12:03 PM
RNS
Chi-Med files Nasdaq Registration Statement
13 Oct 2015 07:00 AM
RNS
Enrolment complete in Savolitinib Phase II trial
12 Oct 2015 02:09 PM
RNS
Holding(s) in Company
14 Sep 2015 07:00 AM
RNS
Presentation at 2015 European Cancer Congress
02 Sep 2015 11:57 AM
RNS
Trial of fruquintinib achieves primary endpoint
19 Aug 2015 12:14 PM
RNS
Termination of R&D agreement with Janssen
28 Jul 2015 07:00 AM
RNS
Interim Results
23 Jul 2015 01:05 PM
RNS
Notification of major interest in shares
23 Jul 2015 01:01 PM
RNS
Notification of major interest in shares
23 Jul 2015 09:01 AM
RNS
Mitsui exchanges shares in Hutchison MediPharma
17 Jul 2015 07:00 AM
RNS
Invention patent granted for SXBXP
06 Jul 2015 07:00 AM
RNS
Notice of Announcement of 2015 Interim Results
29 Jun 2015 07:00 AM
RNS
Blocklisting Six Monthly Return
01 Jun 2015 07:00 AM
RNS
Savolitinib preliminary Phase Ib data presented
13 May 2015 07:00 AM
RNS
Fruquintinib results trigger payments from Lilly
30 Apr 2015 07:00 AM
RNS
Total Voting Rights
24 Apr 2015 12:40 PM
RNS
Result of AGM
22 Apr 2015 11:23 AM
RNS
Director/PDMR Shareholding
16 Apr 2015 01:19 PM
RNS
Director's Shareholding
13 Apr 2015 08:07 AM
RNS
Director's Shareholding
08 Apr 2015 08:18 AM
RNS
Directors' Shareholding
01 Apr 2015 03:48 PM
RNS
Directors Shareholding
01 Apr 2015 02:32 PM
RNS
Exercise of Options
30 Mar 2015 07:00 AM
RNS
Trial of fruquintinib achieves primary endpoint
23 Mar 2015 07:00 AM
RNS
Notice of AGM
18 Mar 2015 07:08 AM
RNS
Notification of Major Interest in Shares

Hutchmed China  Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) is headquartered in Hong Kong and markets its products worldwide.

It was founded in 2000 and listed in London in 2018 under the ticker HCM. 

UK 100